Select Your Region
America
Europa
Afrika
Weltweit
Eine Studie zur Epidemiologie und Prüfung des humanen epidermalen Wachstumsfaktor-Rezeptors 2 (HER2) bei Brustkrebs in Deutschland
A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany
- Krebs
- Brustkrebs
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Abgeschlossen
Diese Studie läuft in
Städte
- Augsburg
- Bamberg
- Bayreuth
- Bergisch Gladbach
- Berlin
- Bocholt
- Bochum
- Bonn
- Coburg
- Dessau-Roßlau
- Dortmund
- Dresden
- Duisburg
- Düren
- Düsseldorf
- Erlangen
- Frankfurt am Main
- Freiburg im Breisgau
- Friedrichshafen
- Gummersbach
- Göppingen
- Göttingen
- Hagen
- Halle (Saale)
- Hamburg
- Hamm
- Hanau
- Hannover
- Heidelberg
- Hildesheim
- Ingolstadt
- Jena
- Karlsruhe
- Kassel
- Kiel
- Konstanz
- Köln
- Lübeck
- Magdeburg
- Mannheim
- Mühlhausen Thüringen
- München
- Münster
- Neubrandenburg
- Oberhausen
- Osnabrück
- Recklinghausen
- Reutlingen
- Rotenburg (Wümme)
- Schweinfurt
- Schwerin
- Stendal
- Stuttgart
- Weiden in der Oberpfalz
Studien-ID:
NCT02666261 ML29763
Studienzusammenfassung
This non-interventional study will collect data from routine diagnostics on HER2 testing of breast cancer in Germany.
Hoffmann-La Roche
Sponsor
NCT02666261,ML29763
Studien-ID
Breast Cancer
Condition
Official Title
A Non-interventional Study on the Epidemiology and Testing of HER2 in Breast Cancer in Germany
Einschlusskriterien
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Samples derived from men and women of age greater than or equal to (>/=) 18 years
- Samples derived from participants with any stage of histologically confirmed invasive breast cancer with HER2 diagnostics performed within routine (histo-)pathological workup or
- (Histo-)Pathological work-up of the tumor sample as at or after start of this study
- Available information on the year of birth of the participant
- No pre-selection of tumor samples is allowed. Tumor samples have to be documented consecutively in the order of their (histo-)pathological work-up.
Exclusion Criteria
- Sample derived from participants with any stage of breast cancer with no HER2 diagnostics performed at the time of routine (histo-)pathological work-up.
- Samples derived prior to the start of this study.
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
